ArticleOPEN ACCESS

Best practices

EBR - European Biopharmaceutical Review
DOI: 10.1177/10983007020040030401
0Citations
Citations of this article
363Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Biomarkers will become important tools for healthcare management and their evolution implies increased use of diagnostic to guide therapies - but why are we continually referring to them in the future tense. Personalised medicine is starting now. ©2000-2007 Samedan Ltd.

Cite

CITATION STYLE

APA

Compagnone, N. A. (2011, March). Best practices. EBR - European Biopharmaceutical Review. https://doi.org/10.1177/10983007020040030401

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free